Trials / Not Yet Recruiting
Not Yet RecruitingNCT05834426
Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers
Omic Technologies Applied to the Study of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Sociedad de Lucha Contra el Cáncer del Ecuador · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to determine the plasma metabolomic profile in diffuse large B-cell lymphoma and high-grade B lymphomas patients before, during and after treatment by ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)
Detailed description
The main question it aims to answer is the correlation between the plasma metabolomic profile of diffuse large B-cell lymphoma and high-grade B lymphomas patients before and after treatment determined by ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS) and analysed with MetaboAnalyst web platform to identify specific over- or under-expressed markers.
Conditions
- Lymphoma, B-Cell
- Neoplasms
- Cancer
- High-grade B-cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Non Hodgkin Lymphoma
- Metabolomics
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS) | For metabolomic analysis, different portions of the blood (plasma and lymphocytes) will be subjected to metabolite extraction by the extraction method defined by Glasgow Polyomics. With protein precipitation, 200 microliters (uL) of the fluid with the metabolites is transferred to a new microtube and must be maintained at -80 °C until the time of metabolomic analysis. |
Timeline
- Start date
- 2023-09-01
- Primary completion
- 2026-08-31
- Completion
- 2026-08-31
- First posted
- 2023-04-28
- Last updated
- 2023-06-22
Locations
1 site across 1 country: Ecuador
Source: ClinicalTrials.gov record NCT05834426. Inclusion in this directory is not an endorsement.